Inventor
CROSIGNANI STEFANO
FR24 patents
⚠️ This page may combine multiple inventors who share the name “CROSIGNANI STEFANO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ITEOS THERAPEUTICS
5 patentsUS9126984B2Sep 8, 2015
4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
ITEOS THERAPEUTICS34 citations90
US10398679B2Sep 3, 2019
Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
ITEOS THERAPEUTICS2 citations69
US9949951B2Apr 24, 2018
Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
ITEOS THERAPEUTICS2 citations69
US9603836B2Mar 28, 2017
Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
ITEOS THERAPEUTICS2 citations69
US9758505B2Sep 12, 2017
3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
ITEOS THERAPEUTICS0 citations38
QUATTROPANI ANNA
3 patentsPFIZER
3 patentsUS10945994B2Mar 16, 2021
Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
PFIZER0 citations60
US9873690B2Jan 23, 2018
3-indol substituted derivatives, pharmaceutical compositions and methods for use
PFIZER1 citations49
US10544095B2Jan 28, 2020
3-indol substituted derivatives, pharmaceutical compositions and methods for use
PFIZER0 citations38
ARES TRADING SA
2 patentsMERCK SERONO SA
2 patentsUS8008302B2Aug 30, 2011
N-hydroxyamide derivatives and use thereof
MERCK SERONO SA0 citations51
US9150519B2Oct 6, 2015
6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
MERCK SERONO SA0 citations50
iTeos Belgium SA
2 patentsUS11427594B2Aug 30, 2022
Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
iTeos Belgium SA0 citations50
US11376255B2Jul 5, 2022
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
iTeos Belgium SA1 citations48